替换
查找内容:
替换为:
全部替换
插入链接
链接网址:
链接显示标题:
请选择网址类型
点我插入链接
插入文件
文件名称:
文件显示标题:
请选择文件类型
点我插入文件
发现错误 发表观点

原文内容

反馈意见

提交 正在提交..... 反馈历史

复制下面的地址分享给好友

确定 正在提交.....
train

你好,

关闭
提交 重做 重新开始 关闭
跳转
  • 新建同级
  • 新建子级
  • 删除
  • 重命名
选择收藏夹
新建收藏夹
公开

取消 确定

1. 基本信息
姓名:
企业:
职位:
联系方式:
邮箱:
2. 请在此填写您的问题,我们将优先安排答疑
提交

报名成功!
课程观看链接如下:
请添加课程助理微信,获得更多信息:
确认
确定
取消 确认

识林

  • 知识
  • 视频
  • 社区
  • 政策法规
    • 国内药监
    • FDA
    • EU
    • PIC/S
    • WHO
    • ICH
    • MHRA
    • PMDA
    • TGA
  • 研发注册
    • 概览
    • 监管动态
    • 研究专题
  • 生产质量
    • 概览
    • 监管动态
    • 各国GMP
    • 中国GMP
    • 中国GMP指南
    • GMP对比
    • 检查缺陷
    • 研究专题
  • 主题词库
  • 帮助中心
  • 关于识林
    • 识林介绍
    • 识林FAQs
    • 功能介绍
    • 团队诊断
    • 联系我们
  • 30天免登录

    忘记密码?

【BD】什么是Business Development?

首页 > 资讯 > 【BD】什么是Business Development?

页面比对

出自识林

【BD】什么是Business Development?
BD
页面比对
笔记

2014-07-26 识林

跳转到: 导航, 搜索

大家好! 尽管我们可能见过面,如果你在北大IPEM项目上过课的话,但这是我第一次在识林™发布文章。

多年来我注意到一些问题,人们对于“业务拓展(Business Development)”一词感到困惑。这主要是由于不同的公司使用“业务拓展”一词来描述不同的职能,困惑由此而来!尽管可能还有其他的区别,这里有两个主要的区别你可能想要了解,从而如果有人告诉你他们在公司做“业务拓展”,你能够明白他们到底在做什么:

1. 许多公司(通常不是医药行业公司)使用“业务拓展”一词描述他们在增加销售、开拓新的国家和商业领域,以及一般来说寻找更多客户购买产品等方面的努力。但是,这些企业,在该职能中并不包括技术收购。

2. 制药企业(和其它生命科学公司)一般使用“业务拓展”一词来形容他们在对由医药公司最终销售的新技术(新化合物、促成技术和一些时候甚至包括现有产品和/或甚至整个公司)的收购和/或许可权方面的努力。大多数企业还将对外授权作为他们业务拓展活动的一部分 — 即,剥离特定技术或产品的利益。

将来我的文章将专注于业务拓展的第二段描述;即,授权或直接收购让企业对该技术拥有专利地位的知识产权。万一有人告诉你他们在公司做业务拓展,在假设他们准确的职能之前, 确切地询问他们在做什么是有好处的。

我希望这些信息可以在人们谈论业务拓展时帮助你更好的理解一些困惑。我计划每月发两篇关于此方面的文章(如果有更频繁的需求的话,可能频率会增加)。如果你有任何问题希望我在以后的文章中给出答案,请邮件联系我pas@pascoventures.com.

Certified Licensing Professional - Paul Stewart先生 2014-07-15
校译:识林-椒 2014-07-25

What IS Business Development?
Written by Paul A. Stewart, Certified Licensing Professional • July 15, 2014

Greetings! Although we may have crossed paths if you were in a class where I spoke at Peking University's IPEM program, this is my first post to ShilinX™.

Something I've noticed over the years is the confusion that people have about the term “Business Development.” This is primarily due to the fact that different companies use the term “Business Development” to describe different functions, hence the confusion! Although there may be others, here are the two primary distinctions that you may want to understand so you can clarify them if someone tells you that they do “Business Development” for their company:

1. Many companies (but not usually companies in the pharmaceutical industry) use the term “Business Development” to describe their efforts at increasing sales, opening new countries and business segments, and in general, finding more customers to buy their products. These firms, however, do not include the acquisition of technology in that function.

2. Pharmaceutical firms (and other life sciences companies) generally use the term “Business Development” to instead describe their efforts at acquiring and/or licensing rights to new technologies (novel compounds, enabling technologies and sometimes even existing products and/or even entire companies) that are ultimately marketed by the pharmaceutical company. Most firms also include out-licensing – that is, divesting of their interests in a particular technology or product – as part of their Business Development activities.

My future posts that you read will focus on the second description of Business Development; that is, the licensing or outright acquisition of intellectual property that allows a firm to have a proprietary position with that technology. Just in case someone tells you that they do Business Development for a company, it is often good to ask them precisely what they do before assuming their precise function for their firm.

I hope this information helps you better understand some of the confusion that occurs when people talk about Business Development. My posts are planned for twice per month (and more frequently if there are requests for more frequent posts). If you have any questions that you would like me to answer in an upcoming post, please send it to me at pas@pascoventures.com.

识林www.shilinx.com,版权所有,如需转载请注明出处

取自“https://login.shilinx.com/wiki/index.php?title=%E3%80%90BD%E3%80%91%E4%BB%80%E4%B9%88%E6%98%AFBusiness_Development%EF%BC%9F”
上一页: OGD7月仅批准17件ANDA
下一页: OGD关于稳定性要求的新决定
相关内容
相关新闻
  • 【BD】一定要持有中国合同的原...
热点新闻
  • ICH 发布新 Q1 稳定性指南...
  • 【直播】25年4月全球法规月报...
  • 【识林新工具】AI知识助手,AI...
  • 【识林新文章】中国无菌附录对...
  • VHP(过氧化氢蒸汽)的“脆弱...

 反馈意见

Copyright ©2011-2025 shilinx.com All Rights Reserved.
识林网站版权所有 京ICP备12018650号-2 (京)网药械信息备字(2022)第00078号
请登录APP查看
打开APP